SCM LifeScience Co

SCM LifeScience Co EBIT Growth

The Year-over-Year EBIT Growth of SCM LifeScience Co (298060.KQ) as of Nov 18, 2026 is 65.21 %. In the previous year, Year-over-Year EBIT Growth was 45.16 % — a change of 44.41% (higher).

EBIT Growth

65.21 %

YoY

44.41%

Last updated:

Year-over-Year EBIT Growth of SCM LifeScience Co is 2025 65.21 % . Year-over-Year EBIT Growth of SCM LifeScience Co was 2024 45.16 % . It decreases by 44.41% higher compared to the previous year.

The SCM LifeScience Co EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
-61.06 KRW
Jan 1, 2021
24.49 KRW
Jan 1, 2022
-3.54 KRW
Jan 1, 2023
-88.69 KRW
Jan 1, 2024
45.16 KRW
Jan 1, 2025
65.21 KRW
The SCM LifeScience Co EBIT Growth history
YEAREBIT GrowthYoY
65.21 %+44.41%
45.16 %-150.91%
-88.69 %+2,403.63%
-3.54 %-114.46%
24.49 %-140.11%
-61.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCM LifeScience Co Stock analysis

What does SCM LifeScience Co do? SCM LifeScience Co Ltd is a biotechnology company headquartered in Incheon, South Korea. The company focuses on the development and production of cell therapy products, including adult stem cell therapies. It also engages in agency testing for cell production and quality assurance, as well as providing adult stem cell consulting services. Additionally, SCM LifeScience operates in the cosmetics and hair growth protein manufacturing sectors. The company has 55 full-time employees. SCM LifeScience completed its initial public offering (IPO) on June 17, 2020. Its stock is listed under the ticker 298060.KQ on the Korean stock exchange, with an ISIN code of KR7298060005. The company's website is http://www.scmlifescience.com/. SCM LifeScience operates within the healthcare sector, specifically within the biotechnology industry. It does not provide details on its founding year, specific product names, or financial figures beyond the IPO date and employee count. The company's activities span drug development for stem cell therapy, cell production testing, and manufacturing of related products. SCM LifeScience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCM LifeScience Co stock

Year-over-Year EBIT Growth of SCM LifeScience Co is 65.21 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth SCM LifeScience Co since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's SCM LifeScience Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — SCM LifeScience Co

All Key Metrics — SCM LifeScience Co